{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-024156","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.121426+00:00","generated_at":"2026-06-04T12:09:19.923964+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Allarity Therapeutics enters $947,000 at-the-market equity offering agreement with Ascendiant Capital","bullets":["Company entered ATM sales agreement with Ascendiant Capital for up to $947,000 of common stock.","Agent commission 3.0% of gross proceeds; expenses reimbursement up to $30,000.","Sales may be made on Nasdaq at market prices; agreement effective until March 2026 or earlier termination.","Placement Shares subject to General Instruction I.B.6 limitations until public float exceeds $75M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-024156","json":"https://secwatch.observer/filing/0001213900-24-024156.json","markdown":"https://secwatch.observer/filing/0001213900-24-024156.md","text":"https://secwatch.observer/filing/0001213900-24-024156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/0001213900-24-024156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/ea0202127-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:09:19.923964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"169cbd5660fb3c33ca74130400178659f67cf0a5","claim":"Allarity Therapeutics, Inc. entered into At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $947,000 (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, Allarity Therapeutics, Inc. (the “ Company ”), entered into an At-The-Market Issuance Sales Agreement (the “ Agreement ”) with Ascendiant Capital Markets, LLC (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/0001213900-24-024156-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Ascendiant Capital Markets, LLC"},{"label":"Value","value":"up to $947,000"},{"label":"Effective","value":"2024-03-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}